USD 6.12
(2.43%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 68.06 Million USD | 100.76% |
2022 | 33.9 Million USD | -51.18% |
2021 | 69.45 Million USD | 23.27% |
2020 | 56.34 Million USD | 878.08% |
2019 | -7.24 Million USD | -101.72% |
2018 | 421.8 Million USD | 1264.07% |
2017 | -36.23 Million USD | 8.72% |
2016 | -39.69 Million USD | -0.63% |
2015 | -39.45 Million USD | 85.14% |
2014 | -265.46 Million USD | -1445.43% |
2013 | -17.17 Million USD | -18.23% |
2012 | -14.52 Million USD | -206.87% |
2011 | 13.59 Million USD | 148.21% |
2010 | -28.19 Million USD | -60.04% |
2009 | -17.61 Million USD | -104.87% |
2008 | -8.59 Million USD | -52.51% |
2007 | -5.63 Million USD | 43.04% |
2006 | -9.89 Million USD | -332.72% |
2005 | -2.28 Million USD | 75.6% |
2004 | -9.37 Million USD | -77.64% |
2003 | -5.27 Million USD | -58.41% |
2002 | -3.33 Million USD | 10.69% |
2001 | -3.72 Million USD | 52.12% |
2000 | -7.78 Million USD | -116.38% |
1999 | -3.6 Million USD | 45.45% |
1998 | -6.6 Million USD | -200.0% |
1997 | -2.2 Million USD | 4.35% |
1996 | -2.3 Million USD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | 10.27 Million USD | -85.78% |
2024 Q2 | 1.83 Million USD | -82.17% |
2023 Q2 | -2.87 Million USD | -213.15% |
2023 Q3 | -393.06 Thousand USD | 86.33% |
2023 Q4 | 72.25 Million USD | 18482.57% |
2023 Q1 | -918.25 Thousand USD | -13.11% |
2023 FY | 68.06 Million USD | 100.76% |
2022 Q4 | -811.79 Thousand USD | -102.46% |
2022 FY | 33.9 Million USD | -51.18% |
2022 Q1 | -361.04 Thousand USD | -100.49% |
2022 Q2 | 2.03 Million USD | 664.21% |
2022 Q3 | 33.04 Million USD | 1521.97% |
2021 Q3 | -3.11 Million USD | -1940.05% |
2021 Q1 | -812.1 Thousand USD | -104.03% |
2021 Q2 | 169.2 Thousand USD | 120.83% |
2021 Q4 | 73.2 Million USD | 2451.38% |
2021 FY | 69.45 Million USD | 23.27% |
2020 Q1 | -8.89 Million USD | -97.61% |
2020 FY | 56.34 Million USD | 878.08% |
2020 Q3 | 24.18 Million USD | 15.79% |
2020 Q2 | 20.89 Million USD | 334.79% |
2020 Q4 | 20.16 Million USD | -16.65% |
2019 Q4 | -4.5 Million USD | -273.4% |
2019 Q2 | -3.16 Million USD | -294.04% |
2019 Q1 | 1.62 Million USD | -96.89% |
2019 FY | -7.24 Million USD | -101.72% |
2019 Q3 | -1.2 Million USD | 61.87% |
2018 Q2 | -7.05 Million USD | 39.12% |
2018 FY | 421.8 Million USD | 1264.07% |
2018 Q1 | -11.58 Million USD | -12.42% |
2018 Q3 | 388.05 Million USD | 5603.27% |
2018 Q4 | 52.39 Million USD | -86.5% |
2017 FY | -36.23 Million USD | 8.72% |
2017 Q4 | -10.3 Million USD | -4.95% |
2017 Q3 | -9.81 Million USD | -30.86% |
2017 Q2 | -7.5 Million USD | 12.93% |
2017 Q1 | -8.61 Million USD | 17.48% |
2016 Q1 | -10.44 Million USD | 48.0% |
2016 FY | -39.69 Million USD | -0.63% |
2016 Q3 | -9.24 Million USD | 3.37% |
2016 Q2 | -9.56 Million USD | 8.45% |
2016 Q4 | -10.43 Million USD | -12.94% |
2015 FY | -39.45 Million USD | 85.14% |
2015 Q3 | -5.63 Million USD | 14.34% |
2015 Q1 | -7.15 Million USD | 62.46% |
2015 Q2 | -6.57 Million USD | 8.11% |
2015 Q4 | -20.09 Million USD | -256.88% |
2014 Q2 | -2.94 Million USD | 12.82% |
2014 Q1 | -3.38 Million USD | 22.05% |
2014 Q3 | -240.07 Million USD | -8042.99% |
2014 Q4 | -19.05 Million USD | 92.06% |
2014 FY | -265.46 Million USD | -1445.43% |
2013 Q1 | -4.87 Million USD | -52.93% |
2013 FY | -17.17 Million USD | -18.23% |
2013 Q2 | -3.06 Million USD | 37.22% |
2013 Q3 | -4.9 Million USD | -60.14% |
2013 Q4 | -4.33 Million USD | 11.5% |
2012 Q3 | -2.94 Million USD | 32.35% |
2012 Q1 | -4.05 Million USD | 29.6% |
2012 FY | -14.52 Million USD | -206.87% |
2012 Q4 | -3.18 Million USD | -8.43% |
2012 Q2 | -4.34 Million USD | -7.25% |
2011 Q4 | -5.75 Million USD | -2834.73% |
2011 FY | 13.59 Million USD | 148.21% |
2011 Q3 | 210.51 Thousand USD | -99.12% |
2011 Q2 | 23.84 Million USD | 607.14% |
2011 Q1 | -4.7 Million USD | 65.37% |
2010 Q2 | -4.57 Million USD | -3.68% |
2010 Q1 | -4.4 Million USD | -520.6% |
2010 FY | -28.19 Million USD | -60.04% |
2010 Q4 | -13.57 Million USD | -206.46% |
2010 Q3 | -4.43 Million USD | 3.09% |
2009 Q2 | -10.35 Million USD | -50.38% |
2009 FY | -17.61 Million USD | -104.87% |
2009 Q4 | 1.04 Million USD | 173.38% |
2009 Q3 | -1.42 Million USD | 86.2% |
2009 Q1 | -6.88 Million USD | -338.1% |
2008 FY | -8.59 Million USD | -52.51% |
2008 Q4 | -1.57 Million USD | 48.12% |
2008 Q3 | -3.02 Million USD | 3.56% |
2008 Q2 | -3.14 Million USD | -265.92% |
2008 Q1 | -858.3 Thousand USD | -61.84% |
2007 Q3 | -2.49 Million USD | -573.34% |
2007 Q2 | 526.74 Thousand USD | 116.77% |
2007 Q1 | -3.14 Million USD | 26.1% |
2007 FY | -5.63 Million USD | 43.04% |
2007 Q4 | -530.33 Thousand USD | 78.73% |
2006 Q4 | -4.25 Million USD | -547.28% |
2006 Q2 | -2.15 Million USD | 23.88% |
2006 Q1 | -2.83 Million USD | -936.3% |
2006 FY | -9.89 Million USD | -332.72% |
2006 Q3 | -656.79 Thousand USD | 69.55% |
2005 Q2 | -1.63 Million USD | -47.23% |
2005 Q3 | 723.76 Thousand USD | 144.39% |
2005 Q4 | -273.43 Thousand USD | -137.78% |
2005 FY | -2.28 Million USD | 75.6% |
2005 Q1 | -1.1 Million USD | 64.35% |
2004 Q3 | -1.83 Million USD | 26.2% |
2004 Q4 | -3.1 Million USD | -69.09% |
2004 FY | -9.37 Million USD | -77.64% |
2004 Q1 | -1.93 Million USD | -20.21% |
2004 Q2 | -2.48 Million USD | -28.36% |
2003 Q3 | -1.57 Million USD | -29.74% |
2003 Q1 | -882.23 Thousand USD | 14.98% |
2003 Q4 | -1.61 Million USD | -2.74% |
2003 FY | -5.27 Million USD | -58.41% |
2003 Q2 | -1.21 Million USD | -37.21% |
2002 Q1 | -712.29 Thousand USD | 43.07% |
2002 FY | -3.33 Million USD | 10.69% |
2002 Q4 | -1.03 Million USD | -64.81% |
2002 Q3 | -629.63 Thousand USD | 33.82% |
2002 Q2 | -951.38 Thousand USD | -33.57% |
2001 Q1 | -368.19 Thousand USD | 82.01% |
2001 FY | -3.72 Million USD | 52.12% |
2001 Q4 | -1.25 Million USD | 21.33% |
2001 Q3 | -1.59 Million USD | -206.07% |
2001 Q2 | -519.65 Thousand USD | -41.14% |
2000 Q2 | -1.44 Million USD | 11.67% |
2000 Q1 | -1.63 Million USD | -81.99% |
2000 FY | -7.78 Million USD | -116.38% |
2000 Q3 | -2.65 Million USD | -83.74% |
2000 Q4 | -2.04 Million USD | 23.0% |
1999 Q4 | -900 Thousand USD | 0.0% |
1999 Q1 | -1 Million USD | 9.09% |
1999 FY | -3.6 Million USD | 45.45% |
1999 Q3 | -900 Thousand USD | 0.0% |
1999 Q2 | -900 Thousand USD | 10.0% |
1998 Q4 | -1.1 Million USD | 15.38% |
1998 Q1 | -2.5 Million USD | -316.67% |
1998 Q2 | -1.8 Million USD | 28.0% |
1998 Q3 | -1.3 Million USD | 27.78% |
1998 FY | -6.6 Million USD | -200.0% |
1997 FY | -2.2 Million USD | 4.35% |
1997 Q1 | -700 Thousand USD | 0.0% |
1997 Q2 | -700 Thousand USD | 0.0% |
1997 Q3 | -300 Thousand USD | 57.14% |
1997 Q4 | -600 Thousand USD | -100.0% |
1996 FY | -2.3 Million USD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Alvotech | -551.73 Million USD | 112.337% |
Collegium Pharmaceutical, Inc. | 48.15 Million USD | -41.354% |
Journey Medical Corporation | -3.85 Million USD | 1866.645% |
Dynavax Technologies Corporation | -6.38 Million USD | 1165.407% |
Intra-Cellular Therapies, Inc. | -139.67 Million USD | 148.734% |
PainReform Ltd. | -9.34 Million USD | 828.476% |
Sunshine Biopharma, Inc. | -4.5 Million USD | 1610.612% |
SCYNEXIS, Inc. | 67.04 Million USD | -1.533% |
Silver Spike Investment Corp. | 7.34 Million USD | -827.355% |
Sunshine Biopharma, Inc. | -4.5 Million USD | 1610.612% |
Bright Green Corporation | -13.12 Million USD | 618.515% |
Esperion Therapeutics, Inc. | -209.24 Million USD | 132.53% |
Aquestive Therapeutics, Inc. | -7.87 Million USD | 964.915% |
ANI Pharmaceuticals, Inc. | 18.77 Million USD | -262.473% |
Alpha Teknova, Inc. | -36.78 Million USD | 285.07% |
Embecta Corp. | 70.4 Million USD | 3.311% |
Safety Shot Inc | -15.08 Million USD | 551.294% |
Procaps Group, S.A. | 42.54 Million USD | -60.011% |
Cosmos Health Inc. | -18.54 Million USD | 467.093% |
China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 2296.809% |
Pacira BioSciences, Inc. | 41.95 Million USD | -62.242% |
Theratechnologies Inc. | -23.95 Million USD | 384.129% |
Harrow Health, Inc. | -24.41 Million USD | 378.845% |
Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 1507.835% |
Biofrontera Inc. | -20.13 Million USD | 438.129% |
DURECT Corporation | -27.62 Million USD | 346.412% |
Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -5072.403% |
Cronos Group Inc. | -73.96 Million USD | 192.031% |
OptiNose, Inc. | -35.48 Million USD | 291.835% |
Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 106.792% |
Kala Pharmaceuticals, Inc. | -42.19 Million USD | 261.304% |
RedHill Biopharma Ltd. | 23.91 Million USD | -184.616% |
Organogenesis Holdings Inc. | 4.94 Million USD | -1276.518% |
Guardion Health Sciences, Inc. | 158.03 Thousand USD | -42972.539% |
Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 1184.016% |
Radius Health, Inc. | -25.79 Million USD | 363.925% |
Universe Pharmaceuticals INC | -6.16 Million USD | 1204.465% |
ProPhase Labs, Inc. | -16.78 Million USD | 505.606% |
Phibro Animal Health Corporation | 2.41 Million USD | -2717.418% |
Procaps Group S.A. | 42.54 Million USD | -60.011% |
TherapeuticsMD, Inc. | -10.27 Million USD | 762.277% |
Viatris Inc. | 54.7 Million USD | -24.44% |
Rockwell Medical, Inc. | -8.43 Million USD | 906.598% |
Aytu BioPharma, Inc. | -15.84 Million USD | 529.619% |
Tilray Brands, Inc. | -244.98 Million USD | 127.785% |
Lifecore Biomedical, Inc. | 12.01 Million USD | -466.626% |
Shineco, Inc. | -22.44 Million USD | 403.215% |
PetIQ, Inc. | 2.13 Million USD | -3094.22% |
Regencell Bioscience Holdings Limited | -4.3 Million USD | 1682.32% |
Incannex Healthcare Limited | -18.45 Million USD | 468.757% |
Neurocrine Biosciences, Inc. | 249.7 Million USD | 72.74% |
Alimera Sciences, Inc. | -20.13 Million USD | 438.113% |
Assertio Holdings, Inc. | -331.94 Million USD | 120.506% |
Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 1132.484% |
Petros Pharmaceuticals, Inc. | -8.16 Million USD | 933.851% |
Clever Leaves Holdings Inc. | -17.89 Million USD | 480.294% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 439.372% |
Avadel Pharmaceuticals plc | -160.27 Million USD | 142.47% |
Hempacco Co., Inc. | -13.12 Million USD | 618.577% |
Talphera, Inc. | -18.39 Million USD | 470.0% |
Alvotech | -551.73 Million USD | 112.337% |
Eagle Pharmaceuticals, Inc. | 35.64 Million USD | -90.979% |
Lantheus Holdings, Inc. | 326.66 Million USD | 79.162% |
Currenc Group, Inc. | -15.3 Million USD | 544.704% |
Kamada Ltd. | 8.28 Million USD | -721.69% |
Indivior PLC | 2 Million USD | -3303.441% |
Evoke Pharma, Inc. | -7.79 Million USD | 973.54% |
Flora Growth Corp. | -57.03 Million USD | 219.344% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 439.372% |
Evolus, Inc. | -61.68 Million USD | 210.349% |
HUTCHMED (China) Limited | 100.78 Million USD | 32.458% |
Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 50.512% |
Akanda Corp. | -32.27 Million USD | 310.902% |